Steve Thomas - IT Consultant

The $19.7BN acquisition of speech-to-text specialist Nuance by Microsoft, announced earlier this year, has attracted the attention of the UK’s active antitrust watchdog — which said today it’s taking a first look to assess whether there are reasons to be concerned about the proposed deal.

A decision on whether the Competition and Markets Authority (CMA) will open a phase 1 investigation will follow in due course.

Currently, there’s no stated timeframe for the regulator to take a decision on that — but a consultation period in which the CMA is inviting interested parties to comment runs until January 10, 2022.

Antitrust oversight of proposed acquisitions can stretch to many months — and can, at the least, lead to major delays to clearing transactions.

In a statement on the development, the CMA said it is “considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services”.

At the time Microsoft announced the Nuance acquisition, back in April, the software giant said it was buying the speech-to-text firm in order to strengthen its presence in the healthcare vertical — where Nuance has developed a number of clinician-support products (such as tech for documenting telehealth visits; a speech recognition tool for clinical documentation; and AI-powered radiology reporting, among other software tools).

The UK’s antitrust regulator may decide the planned acquisition merits further scrutiny — at which point it would open a phase 1 investigation. If after that it decides there is still reason to be concerned it may open a deeper, phase 2 probe.

It may also decide during one of the stages of its process that there are no competition issues of concern and clear the acquisition.

Whereas, on the flip side, if it has concerns it could decide remedies are required before it can go ahead or even order the transition blocked.

Microsoft has been contacted for comment on the CMA’s preliminary probe of its planned purchase of Nuance.

Healthcare has been a vertical of growing interest to tech giants for a number of years — with the likes of Amazon, AppleGoogle, Microsoft and even Facebook all taking an interest in building tools for tracking, monitoring or otherwise supporting health — raising concerns that their ambitions in such a sensitive area will further entrench their dominance and market power as a vital sector steps up digitization.

The UK, meanwhile, is in the process of retooling domestic competition law to take account of platform power — and has said it will be bringing in a “pro-competition” regime which it wants to protect smaller innovators from the market muscle of tech giants.

Ahead of legislation to empower a new Digital Markets Unit, which sits inside the CMA, to oversee big tech the competition watchdog continues to scrutinize M&A activity and other major moves (such as Google’s strategic ‘Privacy Sandbox’ plan).

Most recently, the regulator ordered Meta (aka Facebook) to undo a completed acquisition of animated GIF platform Giphy — a notable development in competition oversight given how few big tech M&As have been challenged, historically — underscoring how the CMA is at the forefront of challenging platform power and ambition (even when — in that instance — the order requires a messy transaction reversal).

Vinehealth, a 2018-founded, London-based digital health startup that’s built an app which offers personalized support for cancer patients while also making it easier to gather patient-reported outcome (PRO) data, including for drug development and clinical trials, has closed a $5.5 million seed round as it prepares to expand into the U.S.

The round, which co-founder and CTO Georgina Kirby describes as a “late seed” — ahead of a planned Series A “in the next 12-18 months” — is led by Talis Capital with participation from previous investors Playfair Capital and Ascension.

A number of angel investors have also joined the round, including Keith Gibbs, former CEO of AXA PPP Healthcare; Pam Garside, partner at Newhealth; Voyagers Health-Tech Fund, led by David Rowan, founding editor of Wired; David Giampaolo, healthcare entrepreneur and founder of PI Capital; Deepali Nangia, venture partner at Speedinvest and Atomico Angel; Faisal Mehmud, VP and former medical director of Bristol Myers Squibb; and KHP, a collaboration between King’s College London, King’s College Hospital NHS Foundation Trust and Guy’s and St Thomas’ NHS Trust.

The startup — which we billed as one “to watch” back in 2019 when we saw the founders pitching at Entrepreneur First’s demo day — combines behavioral science and AI to deliver timely patient support and nudges (for things like medication reminders) so they can more easily self-manage their treatment.

Vinehealth’s platform also acts as a channel through which patients can be remotely monitored by their clinicians as they provide feedback on symptoms and report any treatment side-effects.

So far its app has been downloaded around 15,000 times since being made available in January 2020 — which Kirby confirms covers all usage to date, so both for pure patient-support and for trials/research.

The patient-support app is offered free for cancer patients to download themselves — currently available in the UK and Ireland.

For pharma, Vinehealth provides its platform as a software-as-a-service — supporting drug companies in recruiting patients for trials and gathering PRO to help with R&D and drug development.

“We’ve been focused on pharma since the very beginning and we’re getting a lot of traction there and seeing a lot of opportunity,” says Kirby. “The patient support program and the clinical trial are extremely similar [products]… For pharma they’re different parts of the drug development process but in terms of the delivery of software, the things that patients need throughout that process — it’s extremely similar. So we’ve really narrowed down to that life science offering.”

She confirms Vinehealth is not going down the procurement route of trying to sell to healthcare services directly. So essentially the idea is for life sciences research to fund free provision of the support software to patients. (Although it can’t disclose any pharma customer names as yet.)

While, for monetization, it’s focused on serving the needs of drug companies, Vinehealth is equally keen to be seen as patient-centric — and wants its app to play a key clinician support role that promotes better patient outcomes.

“We have a web dashboard that is accessible through any browser for clinicians and doctors who want to be able to track their patients remotely and do this through running research studies or even within clinical trials,” says Kirby. “Those doctors and nurses can see that data in real-time but they can feed that into either appropriate points of the care pathway — obviously they’re not sitting there on the dashboard all day but there may times at which it’s very useful for them to see specific red flags and be able to know which patient to see see first and also to know how to make better clinical decisions using that kind of more real-time data — rather than the typical [fortnightly or monthly catch up with a patient].”

“So it’s kind of giving them that context and that rich longitudinal data that they’ve never had,” she adds.

Vinehealth has digitized the traditional paper-based questionnaires that cancer patients would typically be asked to fill in during a visit with their clinical team to report their symptoms and provide any wider feedback.

Its premise is that moving that legacy process to a dedicated, user-friendly digital interface supports better patient self management, treatment outcomes and improved quality of life for people living with cancer — given the relative ease of reporting data via an app, combined with the wider support package it offers (it’s worked with charities Macmillan and Bowel Cancer UK to supply support content to the app). 

For example, Kirby says they use A/B testing and AI to configure personalized and timely recommendations to surface appropriate resources, as well as to determine how best to nudge and motivate patients to take medications and manage what can be complex medication regimes for cancer treatment.

Vinehealth’s app wrapper can also dole out positive feedback to encourage patients to provide PRO.

Kirby points to (general) evidence that when patients track their PRO data effectively survival rates can increase — by up to 20%. “Better self management can have such a huge impact on survival,” she says, adding: “We want to show not only improvements in survival but in quality of life too.”

The blend of behavioral science and data-driven support Vinehealth’s approach involves stems from the combined expertise of the co-founders.

“Rayna’s [Patel; co-founder and CEO] background is really in behavioral science; mine is in data science,” says Kirby. “And so when we came together we thought we can really leverage both sides here — and use the data to understand what people are going through and where those nudges can be most effective. And use behavioral science to deliver some really key nudges at the right time with the right wording that can really nudge people to build their habits and be able to feel more in control and be able to actually understand what’s going on and make some better decisions for their own care.

“There are a number of nudges in the app — some small ones, some bigger ones. We build medication nudges and reminders to be delivered in a certain way that is really effective and isn’t just dismissed by patients. We have nudges for logging certain symptoms and what that leads on to — so certain supportive content. So you’re logging anxiety at certain levels, here’s some supportive content that could really help you with dealing with this particular symptom or side effect of your drug.”

“At different times it’s about the timing, the wording and the delivery of that nudge,” she adds. “If you try to change too many things at once research shows that you don’t change anything at all — so we’ve really carefully thought about how we nudge and how we try to help patients build better habits and how often we do that as well.”

Kirby says the goal — in time — is also to use AI to incorporate more advances suggestions into the platform in the future, such as predictive symptom logging (i.e. “what is likely to occur for this particular drug for this particular patient”).

For now, Vinehealth has built a content recommender system which is specialized in oncology and personalized to the patient; tuned to their diagnosis, adapting to their ongoing input, and factoring in content that other similar patients are reading and finding supportive.

On the research side, Kirby says the largest study the platform has been used for to date is an ongoing study involving nine NHS Trusts and 300 patients — which is a piece of research that Vinehealth is undertaking itself.

“We’re planning out a number of clinical trials that are slightly largely than that but still tbc in terms of exact numbers. The US studies are likely to be the larger ones,” she adds.

Health data is of course highly sensitive and Kirby confirms that consent for any third party research purposes is sought separately to the consent which a user of the patient-support product is asked for in order that Vinehealth can process their medical information to provide the service and give them personalized treatment support.

“That data is not shared with anybody — unless they have [given] explicit consent to do that. By just signing up to the platform they’re not consenting to sharing their data as part of a clinical trial. That is a completely separate piece of consent,” she says.

“We make it extremely clear and don’t want to hide any sharing in any way — it has to be really obvious and really clear to a patient. Ultimately everyone wants to support patients. They want to give more opportunities for patients to be in those clinical trials, to be able to capture that data and feed that back in a way where — normally they’re suffering at home with these kind of side effects and that’s never getting back to the pharma company, for example — so we’re making it really clear what we’re doing and why we’re doing that and we give patients a choice.”

Kirby does suggest that, in the future, the startup may also look to be able to provide “properly anonymized” data-sets based on purely aggregated insights provided by patients — so it might, for example, be able to highlight demographic groups that experience particular side effects of certain drugs. However she adds that that is not something it’s doing at the moment — “given our focus on trials and patient support programs”.

In the near term Vinehealth is gearing up for growth via a US launch — which it hopes will happen “early next year” — with the 18-strong team likely to double over the next six months or so and its first US hire already locked in.

“The main thing that we’ve been focused on since we fund raised is hiring a great team and growing that team and investing time in really building that out and making sure that everyone’s aligned on the mission and that we’re really building out a product that’s scalable to be able to take into these new markets,” says Kirby, adding: “Building a startup is all about having great people. You can have great technology but if you don’t have great people then you don’t really have anything.”

Commenting on the seed funding in a statement, Beatrice Aliprandi, principal at Talis Capital, said: “We’re hugely excited to be partnering with Rayna and Georgina: we’d been keeping a close eye on Vinehealth’s growth for several months before we invested in the company, given its unique value proposition where healthcare outcomes work in direct correlation with financial outcomes. It’s a win-win-win for patients, hospitals and pharmaceutical companies, which is rarely the case in the healthcare space where parties are often at odds with one another.

“From our first meeting, the resilience and mission-driven attitude of the founders was immediately clear and is really what made this opportunity so compelling. Both Rayna and Georgina are clearly incredibly driven to improve the lives and survival of cancer patients, and as a team they possess a unique combination of expertise, skills, and drive to make Vinehealth a success.”

Harrison.ai founders Harrison.ai founders Dimitry Tran, Dr. Colin Goldschmidt and Dr. Aengus Tran

Harrison.ai founders Harrison.ai founders Dimitry Tran, Dr. Colin Goldschmidt and Dr. Aengus Tran Photo by Stefanie Zingsheim/The Photo Pitch

Harrison.ai, a Sydney-based company that creates medical devices with AI technology, announced today it has raised $129 million AUD (about $92.3 million USD) in what it says is one of the largest Series B rounds ever for an Australian healthtech company.

The funding was led by returning investor Horizons Ventures, and included participation from new investors Sonic Healthcare and I-MED Radiology Network. Existing backers Blackbird Ventures and Skip Capital also returned for the round, which brings Harrison.ai’s total raised over the past two years to $158 million AUD.

Harrison.ai announced it has also formed a joint venture with Sonic Healthcare, one of the world’s largest medical diagnostics providers, to develop and commercialize new clinical AI solutions in pathology. The partnership will focus first on histopathology, or the diagnosis of tissue diseases.

This follows another joint venture Harrison.ai formed with I-MED Radiology in early 2020, creating Annalise.ai to develop AI-based radiology diagnostic support tools.

Harrison.ai CEO Dr. Aengus Tran told TechCrunch he became a doctor to help as many people as he could. “As I looked more into artificial intelligence, I fell in love with the idea of using AI to help more people than I ever could my lifetime.”

Harrison.ai was started with his brother Dimitry to scale the global capacity of quality of healthcare by giving clinicians AI-based tools. Dr. Tran said that Annalise.ai was able to release its first regulatory-approved product within 18 months, an AI tool that detects clinical findings on chest X-rays.

The funding will also be used to hire more AI data scientists and engineers, and form clinical partnerships around the world to expand into new healthcare areas. Harrison.ai says its AI-based technology can help improve the diagnosis process in places where there is a healthcare shortage.

“COVID has intensified the inequities and struggles the global healthcare system was already under, especially in critical areas like radiology and pathology,” said Dr. Tran. “For the past decade and more we have seen a critical shortage of radiologists in both developed and developing markets, and that has only gotten worse as COVID led to further skills shortages and a backlog of elective procedures and requirements.”

He added that Harrison.ai’s AI-based technology is designed to help scale healthcare systems, and are not meant to replace clinicians. “We’re giving them the tools to make critical healthcare decisions quickly, and at scale, with the help of artificial intelligence.”

Harrison.ai currently has teams in Australia, the United Kingdom and Vietnam, and plans to expand into other countries soon. Its products are ready for market in Australia, the UK, Europe and some Asian countries, Dr. Tran said. The company’s goal is to expand into other markets, with the goal of helping one million patients a day.

 

Amazon announced a new version of its Halo fitness band at its September hardware event, and now you can lock in a pre-order. Halo View, Amazon’s first wearable with a display, is $50 during the pre-order period. It’ll typically cost $80.

The device, which will ship sometime in December, comes with a year-long Halo membership. The plan includes workouts and nutrition guidance, and it typically costs $4 per month.

Halo View has a similar design to Fitbit’s Charge bands. The AMOLED color screen displays details about your live workouts, activity history, blood oxygen and sleep scores, among other things (some of those features are exclusive to the Halo subscription). You can view text notifications too.

The swim-proof device contains a skin temperature sensor, heart rate monitor and an accelerometer. Amazon claims the battery runs for up to seven days on a single charge, and that it will fully recharge in two hours.

Although Halo View doesn’t have a built-in microphone, there is integration with Alexa. If you connect to the voice assistant through the Halo app settings, you can ask an Alexa-enabled device to tell you about your health summary, sleep quality and other information.

Amazon says privacy was a key consideration in how it designed Halo. “There are multiple layers of protections in place to keep data safe and in your control,” the company claims. It also pledged not to sell health data that’s linked directly to you. You’ll have the option to download your health data or delete it from the Halo app at any time too.

Editor’s note: This article originally appeared on Engadget.

Startups geared towards men’s sexual health have been doing a brisk trade for a few years now. But while the early wave of tech businesses mostly aimed to provide (easier) access to pharmaceuticals for treating health issues like erectile dysfunction (e.g. Roman), perhaps also offering hormone tests and bespoke vitamins claimed to reduce hair loss or boost libido (Manual) — and with some branching into broader telemedicine plays over time (Ro) — more recently the category has expanded to dial up attention on men’s mental health too.

It’s a welcome — and some might say, long overdue — development.

Here the UK seems to be a bit of a hotbed of entrepreneurial activity. Back in September, for example, we covered a seed round for UK-based Mojo, a subscription service for men’s sexual well-being, touting therapy instead of pills as the answer to erectile dysfunction.

And while not exclusively for men, UK-based Paired is offering couples therapy via an app.

Well, here’s another UK-based subscription service with a holistic approach to men’s sexual well-being and self care — founded in the same year as Mojo (2019): The similarly named Remojo offers tech tools and in-app programs to support men with sexual health concerns — with a first focus on helping people quit porn. (Hence ‘Re’mojo.)

Take a spin around Remojo’s website and its marketing soon implies a range of benefits could flow from quitting porn — not just time and attention saved but better in-person relationships and even, potentially, a resolution to health problems like erectile dysfunction. So there looks to be a fair amount of overlap in this burgeoning male sexual well-being space.

Aside from variations in pricing (Remojo’s subscription plans are cheaper than Mojo’s), the initial difference mostly seems to be one of emphasis; aka, how to get men interested in the first place.

On that it seems a fair bet that more men consume porn than suffer from erectile dysfunction. Although Remojo’s target is men who both watch porn and want to stop. But sole founder, Jack Jenkins, is quick to emphasize that the subscription service isn’t only for men with porn addiction.

Rather he says it’s designed to address a full spectrum of reasons why guys might want to stop consuming pornography — from simple self improvement (and wanting to get more control over what’s playing on their minds); to those who find their porn consumption habits are getting in the way of real life (and real relationships); to guys with religious convictions who feel shame around using porn, however rarely they may do it, and want help to live up to a sought for spiritual standard.

Per Jenkins, a key cohort of Remojo’s users are thus Christians, Muslims and Hindus looking for help to live up to religious ideals — and maybe also seeking a non-judgmental support community for an issue that can be taboo for them to talk about in their usual social circles.

Remojo says it’s getting circa 50,000 signups per month for its subscription programs (which cost $4.99 for one month; or less if you sign up for the 3-month or year-long plan) — with users hailing from all over the world (at least where Internet access is easy) — suggesting porn consumption is a very universal concern.

Currently, Remojo’s biggest markets are the US, UK, Brazil and India. Content in the app is in English so it’s also growing in other English-speaking markets, per Jenkins. While the typical Remojo user is a guy aged between 16-35 — aka, a digital native who’s “grown up with instant access to porn at all times”.

With traction like that it’s also, unsurprisingly, attracting interest from investors.

Over the past 12 months, Jenkins says Remojo has raised £1.6 million (~$2.1M) in pre-seed funding from a number of business angels, including Jens Lapinski (former TechStars Berlin MD and CEO of Angel Invest) and Jag Singh (also of TechStars Berlin and Angel Invest), along with a number of other angels in the banking/finance space, plus some (unnamed) founders chipping in.

It’s now in the process of raising a Series A, according to Jenkins — who says it’s targeting £5M-£6M (~$6.7M-$8M) and expecting to close the round “by January” (hence he says they’ll “probably” skip a seed and go straight for the A).

Remojo’s website touts what it bills as a “90 day reboot” — which it says is its most popular subscription plan — for quitting porn.

If the tech really works that would imply major user churn every three months. But the stickiness and easy accessibility of online porn means relapsing is a perennial risk and a blocker tool is always likely to be helpful, argues Jenkins. So he doesn’t sound at all concerned about revenues drying up (i.e. from succeeding in its mission of getting men to hard quit porn).

In-app courses are another way for Remojo to provide broader, on-going utility and appeal — hence it’s offering support for other aspects of men’s sexual health and well-being; which may have been linked to (and negatively affected by) their consumption of porn (but which won’t necessarily instantly improve if/when they do stop).

Jenkins bootstrapped the business himself initially — launching an MVP which let users custom block content on their smartphones to cut off access to sources of porn.

Now the software is available cross-device, for Android, iOS, Windows and macOS. And it bakes in a lot more than a simple adult content blocker that puts up a literal barrier to accessing online porn — such as the aforementioned behavioral change courses, CBT techniques and a wider support community.

Future features in the works include AI-driven porn content identification to enhance the software’s powers of blocking/filtration, with Jenkins saying it’s working on developing models that will use computer vision and audio to detect pornography viewing as it’s in progress so that the software will be able to intervene in real-time too.

The current mix blends custom blocking with supportive resources.

“It’s a hybrid of a few things. You’ve got research around habit formation and habit breaking — using the findings and principles from that field. We have our in-app content director [Noah Church] has been coaching people to get free from porn addiction for seven years — he’s got a YouTube channel where he’s been delivering courses and coaching [for years],” Jenkins tells TechCrunch.

“One of the foundations of the structure of the app is the ‘choice model’ — which was the recovery model developed by [Dr] Paula Hall — who’s one of the leading experts, if not the leading expert, on porn and sex addiction in the UK.”

Other bits Remojo folds into its behavioral change mix are practical user insights from the program; access to an anonymous support community of others; and tools for users to track progress and be helped to stay committed/accountable (such as an accountability partner and install/PIN protection).

A core component of its program is to start the user with a full ‘reboot’ — aka a period of sustained abstinence from consuming porn (where Remojo’s blocking tools and accountability features clearly play a key role). The idea is to help guys get space to develop alternative habits — and here its suggestions for filling the hole left by not consuming porn includes stuff like mindfulness, exercise and participation in (porn-free) hobbies.

Jenkins says the overarching goal is changing mindsets/thinking patterns — and male self improvement more generally — hence course content covers related/follow-on areas, such as habit change, addiction recovery and overcoming sexual dysfunction (where it’s overlapping with Mojo).

Future course content is also slated to cover broader areas like dating and help with improving a relationship/sex life with a partner, as well as courses that will aim to tailor advice for specific religious beliefs.

“And for people that are maybe in a more difficult place, [we offer help with] building a more fulfilling life so that they don’t need something like porn to fill an emotional hole,” he adds.

While some porn users may have deeper psychological issues linked to their use (such as childhood abuse), Jenkins argues that porn consumption itself may not have any deeper significance than being a “convenient” release. So it’s not always necessary to psychologize consumption.

The app therefore aims to avoid judging — putting its focus on simply supporting men to regain control over their time and attention. And, well, sticking it to the attention-sucking porn industry in the process.

“[Porn use is] not necessarily driven by any deep psychological issue — it’s just very stimulating, very compulsive material that just taps into people’s fundamental evolutionary drives and just hijacks it. So people can end up just watching porn purely because it’s just there and it’s so compelling,” he argues.

“This problem is so universally shared. It’s basically almost all men under 35 — everywhere around the world, religious, non-religious. It’s just a huge issue and it’s very, very difficult to generalize,” he adds of the pull of online porn. “You can have people who might have such a severe addiction that they might be watching porn from anything like 3-7 hours a day all the way through to someone who maybe you’re a Muslim and you watch it once a month but that’s a huge problem for you because Islam has zero tolerance for that. And it’s affecting your self esteem and disconnecting you from god and so on.

“So the spectrum is so broad that it’s very difficult to generalize. I think what’s really gratifying for me and the team is all the different stories, comments, reviews we get from people about how their life’s changing — and in different ways.”

Zooming out for a sec, concern about online porn viewing is something of a decade+ preoccupation of the UK government at this point — one that’s now driving ministers to implement sweeping online safety legislation, fuelled by a concern over the harms caused to children by easy access to inappropriate content online.

Remojo’s premise is, similarly, that if guys are exposed to limitless porn from a very young age it sets them up for problems with a range of sexual well-being issues later on (and, well, 50k men a month does suggest it’s onto something.)

An earlier attempt by the UK government to mandate age verification for accessing adult websites faltered, back in 2019, after a backlash over security and privacy concerns, and the viability of imposing and regulating age checks.

Guys opting into their own custom porn blocker and support-to-quit community (for a fee) certainly looks a lot easier to implement.

Jenkins says he formulated the idea for an app-based support tool for quitting porn after deciding to make the switch himself — not because he was addicted to porn but rather as “a conscious choice to live better and be my absolute best”.

It was while he was looking for support to quit that he came across subreddits with over a million users also seeking the same kind of support — and from there he started to realize the scale of the problem and the potential business opportunity.

“I started the process of quitting and cutting porn from my life completely and started looking for something to just put up a guardrail — and just block it and filter out all of that content on phones and computers, and there wasn’t really anything good out there,” he recounts. “So, being somewhat entrepreneurial, I started exploring the problem more — I thought I can’t be the only guy who wants to do this or who’s feeling like this — and so I started reaching out to people on Reddit through DMs who were actively talking about quitting porn, or porn addiction, or just problems with porn and the affect it has on their lives.

“I started doing interviews with them and I was blown away by — one — how many people were talking about it on Reddit. So there’s about 1.3 million people in subreddits just dedicated to, basically, quitting porn; and then also how eager they were to speak to me and share all kinds of person stories and information and how desperate they were for a solution.”

“After doing that initial user discovery I just started work on it immediately — in December 2019 — because I’d never seen that level of problem validation before for any idea that I’d ever had,” he adds.

“It started out being about blocking and then, over time, my understanding of the problem that people are facing — and actually how you help them make the behaviour change — break the habit or break the addiction, just change their behavior and how they think — there’s much more to it than just blocking.”

Just as Mojo is hoping that treatment for erectile dysfunction can be a way to reach men with wider therapy offers (including support for porn addiction), Remojo also intends its tools to be more expansive: Jenkins says it’s aiming to replicate the app-based framework it’s devising for porn so it can be reskinned and applied to tackle a range of “modern, behavioral, digital addictions and compulsions that no one’s really dealing with” — from online gambling to social media and computer gaming addiction.

“We’re going to use our framework to help people quit gambling, quit compulsive gaming and also reduce or cut social media. These will be separate brands but using the same technology, the same framework to guide people to better habits or complete abstinence from those things as well,” he says. “The exact same framework applies — we would just really change the in-app courses. But the rest of the system is exactly the same in terms of what works for habit change, behavior change and overcoming these digital addictions.”

So maybe — ultimately — Remojo will also be building products targeted at women.

(It’s also yet another sign of how far attitudes around social media have skewed negative that quitting porn and quitting Facebook are being uttered in the same breath.)

Another development on its roadmap is to create its own custom OS — one that’s minimalist by nature and aims to put the user in control over all the digital things trying to gobble up their attention.

“We want to build a custom operating system for Android phones and also for desktop devices,” he tells us, saying it will use some of the forthcoming Series A funding to start work on that with the goal of “releasing a handset for digital minimalists with all of these digital wellness controls built into the operating system itself”.

The plan for the next 12 months — when Remojo expects to be flush with Series A cash — will also be to dial up its messaging.

On that, Jenkins says it wants to “start a global conversation” to change many more minds about porn consumption — and try to normalize the notion of quitting porn so it becomes as ‘vanilla’ and unremarkable as a person saying they don’t drink or smoke.

“What we’ll be looking to do with the Series A is… break the taboo around the topic. And make this as normal and widely accepted as saying you don’t drink, you don’t smoke, you don’t eat meat and so on. Make this lifestyle choice an acceptable mainstream topic or choice,” he adds.

French startup Lifen has raised a $58 million (€50 million) funding round. The startup has been working on digital infrastructure for the healthcare industry, starting with medical reports. 600 healthcare facilities are using the product to send and receive medical documents.

And each customer is using Lifen intensively as it represents 2 million medical documents sent to 240,000 doctors each month. Patients can also retrieve documents from Lifen directly as well.

Creadev and Lauxera Capital Partners led today’s Series C round. Existing investors Serena and Partech participated in the funding round once again.

Lifen started with messaging in the healthcare industry as the company saw an opportunity for an upgrade. Many stakeholders in the industry used to rely on good old physical letters to send medical documents. And hospitals were stuck as they couldn’t just switch to email due to data privacy.

The startup built a document platform that works with several electronic messaging protocols designed for medical records. It makes it much easier to go paperless and send reports automatically.

Lifen has also added some machine learning on top of its document product. The company tries to detect key information automatically to turn documents into structured data. For instance, the startup tries to automatically identify the name of the patient as well as sender information.

And now, the company wants to go beyond messaging with a full-fledged digital platform for the healthcare industry. Healthcare facilities can use Lifen to start using other e-health apps.

Lifen has its own app store that references all apps that work with Lifen’s user management system and connect with Lifen. This strategy has worked particularly well for Salesforce.

With today’s funding round, the company plans to hire more than 200 employees over the next 18 months. By 2025, the startup wants to work with 1,500 hospitals and 200 e-health solutions.

The market for complementary and alternative medicine — a wide-ranging area that includes practice-based work like yoga as well as a huge range of supplements and everything in between — has been on a massive upswing , with the global industry valued at $82.3 billion in 2020 and growing at a fast clip in the years ahead.

Now, a company called Fullscript, which has built a wholesale backend and storefront builder to power the supplements businesses of alternative health practitioners providing these services, is getting a big infusion of cash to meet the opportunity. The Ottawa, Canada-based company has raised $240 million, funding that it will be using to continue expanding its business across North America, and developing more tools to serve its customers: practitioners building complementary and integrative treatment plans (bringing together both traditional and modern approaches) for their patients.

“We believe integrated medicine will be medicine in the future,” Fullscript co-founder and CEO Kyle Braatz said in an interview. “Sixty percent practitioners are already focusing on wellness and prevention. It’s more than just pharmaceuticals, and patients are doing more than just popping a pill.” The company today offers a stock of some 20,000 products from some 300 brands.

The investment is coming from HGGC and Snapdragon Capital Partners — respectively a mid-market firm more known for private equity investments and a firm that invests in primarily health and wellness businesses. Fullscript’s valuation is not being disclosed, but for some context, the company has been around since 2012 and had only raised about $25 million previously, growing largely by being bootstrapped. And one reason that it will have come to investors’ attention now is its financial track record on its own steam: it’s going to make $300 million in revenue this coming fiscal year, growing from a mere $40 million five years ago.

Fullscript is based in the same city as Shopify, and Braatz likened a little of what his company does in its own B2B2C model to what Shopify has achieved in the world of e-commerce.

Just as the latter has provided an easy way for companies selling online to build and operate their own web-based storefronts (a business that has been huge, and seen Shopify extending into a lot of adjacent areas as a result), Fullscript is addressing the needs of practitioners online.

Among Fullscript’s services, it helps them source supplements; set up and fulfill prescriptions for those treatments from Fullscript’s dispensary, either to pick up in their offices or have delivered to their homes; manage their patients’ bigger treatment plans through an integrated approach that brings data from these treatments into a patient’s wider electronic health records; and provide supplementary reading and other educational materials about the supplements that are being dispensed.

“Just as Shopify empowers merchants, we empower practitioners,” Braatz said. And just as Shopify has brought a number of different tools online for its merchant customers to build out their businesses on the Shopify platform, so too is Fullscript developing more technology to grow its proposition. That will include more analytics for its customers, more tools for patients to monitor their own progress and purchases, and so on.

Fullscript’s rise comes amid a much bigger push for online health services, and specifically those geared at selling medicines and supplements. That means more potential competition from Amazons of this world (Amazon being already a major destination for vitamins and other supplements), and more attention being paid to others like Ro trying to make headway in this space. But also a greater acceptance and understanding that the online component of this business is here to stay.

But it’s not all smooth sailing. Complementary therapies have been a mixed bag when it comes to general acceptance and usage of them.

On one side, consumers, and a widening pool of traditional and modern practitioners are increasingly looking at these alongside the pharmaceutical approach. But on the other, there are a few reason why that hasn’t been more mainstream. For starters, insurance companies do not always provide coverage for these treatments as they do for the more standard medical treatments. One of the reasons for this is that, for better or worse, pharmaceutical approaches are trialled, tested, approved by regulators and generally entered into a realm of acceptance that makes it more likely that an insurance company (or practitioner) will opt for those treatments. The same has not been the case for supplementary medicines, not least because some of the effects might be harder to quantify. And partly because of that, or even from direct experience, there are plenty of reputable skeptics when it comes to those effects.

Insurance is not part of the backend for the moment for Fullscript, and all of the payments for products are made by patients directly themselves.

In the defense of integrative approaches, however, there are plenty of reasons why consumers and the medical industry might also criticize the pharmaceutical approach, too (not least because it’s not 100% foolproof, the costs, the side effects and so on). Indeed, Braatz noted that attitudes towards integrative approaches are gradually starting to change, not least because of the many reasons that conventional approaches do not work perfectly.

“I think the whole integrative market is just starting to leverage insurance,” he said. “Practitioners starting to be compensated because compensation is evolving from volume to value-based. And we see hospital systems starting to build and acquire integrative clinics to keep patients out of hospital systems.”

That evolution, in effect, is as much a part of the investment strategy here as the current business is.

“We are long term believers in the Fullscript story, and we thought that its platform, the tech they developed, and the reviews of that we’ve seen of it from the industry, would be an exciting investment. There is a ton of potential,” said Bill Conrad of HGGC.

The Great Resignation, the pandemic-caused seismic shift in the way we work, play and live, and the boom of the creator and influencer economy has led to a surge in apps designed to serve those creators. In fact, we had a very long-winded discussion about it at TechCrunch just this week.

It’s hard to know which apps are going to change the game and which are going to sink, but Emergence is betting big on a platform called Talent Hack.

The company is today announcing a $17 million Series A financing round, led by Emergence, with participation from existing investor Global Founders Capital.

The startup was founded by Alexandra Bonetti, making Talent Hack the first Latina female-led startup in the Emergence portfolio.

Before Talent Hack, fitness creators were stitching together a handful of platforms to run their business, from Paypal to Wix to email automation software, and more. Or, they were working for a studio or a big box gym without the freedom and flexibility to set their own course.

Talent Hack provides software that streamlines all of that, complete with payment processing, website design and publishing, scheduling software, email automation, and CRM.

This allows fitness creators to focus on their clients and their classes, rather than dealing with running their business via software.

Talent Hack says that creators that switch over to Talent Hack increase their revenue by an average of 280 percent.

One differentiator between Talent Hack and some of its competitors is that it doesn’t aggregate fitness creators on behalf of the customer, but rather focuses on letting the creator build out their audience with the tools they need to be successful.

“We’re building a model that doesn’t attack the creators’ relationship with their clients,” said Bonetti. “We’re not building a marketplace or shopping talent around to other clients. We really protect them and our client philosophy is we never get in the way of the client/talent relationship. We really go out of our way to build that out.”

Talent Hack makes money by charging a processing fee for sessions booked through the platform, which is paid for by the client and not the creator. This fee ranges anywhere from three to 10 percent, and is algorithmically based on geography, spending patterns, and attendance at their classes, among other factors.

The startup also provides educational tools and courses to creators who are looking to grow their business. The new funding will be used to expand this program, and will also be used to build out Talent Hack Co-Spaces, which will give creators the ability to train in one-on-one sessions.

“The biggest challenge we have is a very exciting market with a lot of capital, a lot of investment, both horizontally and within our vertical,” said Bonetti. “And this is a very fragmented industry and that’s the value in bringing these creators in one place. Once once we’re able to really do that, there is so much to build to serve them. But like any industry that’s starting to aggregate for the first time, that’s a hard challenge.”

Truveta wants to collect privacy-safe medical data from around the United States on a regular basis, making it available for researchers to sift and parse. The company is making real progress towards that goal in product terms, and this morning said it raised another $100 million, giving it a capital base of around $200 million in total.

But the financial aspect, and the fact that Truveta has secured more partners in the medical world to supply it with information, are ancillary to the fact that the startup has started to make its platform available to external parties.

Truveta partners with around 20 medical providers, aggregating regular de-identified data from 42 American states and myriad patients into its collection. From there it has built a software service that allows researchers and other users to ask questions of the collected data. TechCrunch was given a tour of the Truveta product, which, as chart nerds, we liked.

But frankly, your local technology writer is not precisely the Truveta end-user. Instead, the product is aimed at individuals with their hands in the public health domain. To that end, the company’s product lets researchers include and exclude elements of the population, before dropping the user into a Jupyter Notebook, from where they can build a dashboard with data that updates daily.

Truveta has eyes on 16% of all clinical care in the United States, per CEO Terry Myerson, who formerly worked with Microsoft.

The company shared a grip of COVID-19 related material this morning that it has gleaned from its own product. It turns out that “adverse events” happen to fewer than 1% of folks with a full COVID-19 vaccine, with Moderna patients showing 40% more than those who received Pfizer. Given that I am a Moderna Man and my spouse is Team Pfizer, I was amused by that latter stat. Perhaps I’ll mix-and-match my booster?

Truveta is more interesting for its long-term potential than for what it has managed to learn thus far, in my view. It’s good news for our country that the company is starting to open up access to external parties, and has a product that can ingest mountains of data and share it in a privacy-safe manner. Our healthcare system is expensive, siloed, antiquated, and rife with inefficiencies. Truveta could make things a bit more open and, if we are lucky, clear.

What will prove interesting from this juncture is how Truveta converts itself from an interesting — and now operating — project into a business. It has a pretty firm anti-advertising stance, saying in its self-description that its service is “licensed for ethical medical research [and] not to target advertising to patients or physicians.” Fair enough, but do researchers have the coin to make the project work? Perhaps Truveta will sell its service back to its data providers, each contributing both data and regular fees to the company?

Truveta notes in its self-produced bio that it pays taxes. Hence, it isn’t a non-profit. That means at least an attempt at future profitability, which will keep our business model questions at the front of our minds. But with $100 million in new capital, Truveta is hardly about to run short on cash.

All told, Truveta has rapidly scaled its partner base and tech stack to the point of market viability. Let’s see what demand is attracted, and how quickly positive health and business outcomes can be ascertained.

Billionaire VC Tim Draper (via Draper Associates) has led a $6 million Series A in wellness tracking startup, Vivoo. Also participating in the funding round is ONCE Ventures, Revo Capital, 500 Startups (which backed its pre-seed), Global Ventures, and (the female-led consumer tech startup focused) Halogen Ventures.

The personalized nutrition and lifestyle startup sells subscription-based at-home urine test kits that work in conjunction with an app. Its machine learning technology remotely analyzes a user’s peed-on test strip to serve up custom ‘wellness’ insights, then and there, offering recommendations across a range of areas such as nutrition and biological function.

The startup’s founding team is led by CEO and co-founder Miray Tayfun, a serial founder and bioengineer by background who graduated from Stanford’s postgraduate programs. Other co-founders for the 2017-founded startup are George Radman, CFO; and Gozde Buyukacaroglu, COO.

Vivoo launched its subscription service in July 2020 and has amassed more than 50,000 users from over 100 different countries in a little over a year.

It’s says it’s expecting its revenue to grow 10x in 2021 — and points to predictions that the mobile health app market will be worth $236BN by 2026.

It does currently offer a one-time pack (of 4 “wellness” tests for $34.99) — but otherwise it’s selling a 3-month subscription offering ($15.99pm) or a 12-month subscription which works out to $7.99pm.

While Vivoo is shipping its kits around the world, its biggest markets are the US and Canada — followed by the UK and Australia. (The Anglo bias is down to content currently only being available for English, and “tailored for Western cuisine”, which puts some obvious limits on global appeal.)

Typical users to-date are “health conscious individuals” looking for “actionable insights to improve their diet, health, energy, sleep and overall longevity”, per Tayfun.

“The Keto diet audience were the early adopters for our product but we’re seeing interest from a wide age and geography at the moment,” she tells TechCrunch. “Our biggest audience is 25-45 year old women users followed by the same age group male users. “Around 80% of our users also use other trackers such as wearable devices and who did or would like to do tests like genetic and microbiome at-home tests.”

Vivoo says the Series A funding will mostly go on expanding its team to further scale the business — with a focus on the US, where it has already inked partnerships with retail outlets including Amazon and Walmart to distribute the product.

Funding will also go on expanding the product, with additional test kits planned and a new premium offering incoming that will expand what can be tracked and offer integration with wearable data from products like the Apple Watch to further boost utility.

The quantified health trend has been evolving for several years now, beyond basics like step counting and sleep tracking — and getting, well, a whole lot more interesting and intimate. But the challenge for this new wave of ‘personalized wellness/health’ startups is not just gathering accurate data and avoiding privacy pitfalls, it’s making good sense of the data they gather.

Whatever the chosen biomarker, such startups have to be able to extract genuinely useful signal from biological noise (remotely in Vivoo’s case); and, if applying AI (as it is; and most startups in this new wave are), they also need to begin with enough training data to build algorithms that can robustly identify patterns across a diverse user-base and transform a snapshot of individual data into genuinely beneficial lifestyle nudges for the individual in question. Aka: Eat this, drink that, exercise now — as one such startup (January AI) does it.

Startups in this space are targeting a variety of biomarkers to sell the promise of custom nutrition/lifestyle advice that claims to offer a superior spin on the basic tenets of eat fresh, exercise often.

Some — like Ultrahuman and Zoe — are tracking blood glucose and/or getting users to collect and send in stool samples for analysis of their microbiome. And here the focus may be on diet/tackling obesity or pro-fitness/elite sports (or both).

While, for a female fertility use case, the biomarker in question can involve tracking vaginal mucus or body temperature, as with Kegg and Natural Cycles respectively. Or using saliva to track hormones (Inne).

Certain approaches to personalized wellness/health require more invasive interventions than others to acquire the necessary biological data to perform the tracking. But it’s fair to say that all ask users to get pretty up close and personal with their own bodies.

Collecting stool samples is obviously a fairly messy business. And gathering real-time blood glucose measurements — at very least — means being okay with pricking your finger, for example.

One game-changing technology — continuous blood glucose monitors (CGMs) — yields a steady flow of pretty fascinating diet and lifestyle data but you’ll need to be comfortable wearing a sensor that contains a semi-invasive filament embedded in your interstitial fluid in order to play. (And putting that kind of ‘wearable’ in place typically means applying a spring-loaded hollow needle that fires the filament into your flesh… so it’s definitely not the Apple Watch and isn’t going to be for everyone. Although researchers are trying to come up with truly non-invasive CGMs — such as GraphWear’s years-long push to build a skin-surface-level wearable for glucose monitoring; so if they pull that off it will be a major breakthrough for scaling personalized health.)

Vivoo — by contrast — is using a fairly simple, low mess, non-invasive avenue to get snapshots of biological data: Pee sticks.

“We chose urine rather than saliva or blood to start because it’s easy to collect and analyze and can be used to measure a high number of the body’s performance variables. 4,000 metabolites can be seen in the urine,” says Tayfun, suggesting it plans to branch out in the future. She adds that the startup sees CGM as a “complementary technology” — envisaging a partnership with a device maker down the line (“since the data is complementary to Vivoo data sets, and our users are always seeking more information”).

“Our biggest criteria when we’re looking for other tests or tracking devices is it should be at-home, not sending to a lab and waiting for your results for weeks. We believe that the process is frustrating and old-fashioned for ‘at-home’ lab tests,” she adds.

Vivoo’s approach is simple: It ships a pack of individual urine test strips to subscribers. (And for anyone who’s used an at-home pregnancy test the basic process will be familiar.)

Each Vivoo test strip contains a series of colored boxes. After the user has peed on these they just have to wait a couple of minutes and then take a scan of the strip using the camera in the app — which uploads the image data for analysis. (So the app is examining the pre- and post-pee colors to compare changes — and using that to determine urine test results.)

Vivoo says it’s using machine learning technology to perform this remote urine analysis — including what it bills as “advanced image and color processes for calibration, validation, and verification” (i.e. given how much variation there is across smartphone camera hardware). Once the user’s data has been crunched, the app then returns them custom wellness advice based on the machine learning tech’s remote read of their urine test.

Advice dished out may include suggestions on how to could tweak your diet to boost a certain nutrient if the urine analysis suggests it’s low (e.g. calcium or vitamin C) — such as ‘eat more calcium-rich arugula’ or ‘have a bowl of vitamin C-boosting strawberries for breakfast’ — or it might give an alert about a possible infection.

Hydration is another tracked measure. And, here again, Vivoo’s tech is using a color change analysis to determine whether a user is getting enough to drink — and, if it thinks not, the app will nudge users to drink more (by, say, recommending they drink 10 glasses of water per day).

While it’s making recommendations it says are evidence-based and associated with a healthier lifestyle, the startup’s website is careful to specify the product is for “wellness” purposes only — and that the app is not a medical diagnostic device.

Vivoo says its product offers a range of wellness “parameters” that health-conscious users can track — including overall hydration; menstruation; whether they have an infection (e.g. UTI) or bodily inflammation (tracked by analysis of white blood cells); their urine’s acidity and alkalinity level (used as a dietary indicator); ketones (mainly for those on a ‌‌ketogenic‌ ‌diet); and the function of their liver and kidney.

“Users can access data on 15 health factors, including hydration, pH balance, ketones, calcium, magnesium, Vitamin C, free radicals, kidney function, liver function, UTI risk, activity levels, stress levels, menstruation, and overall wellness,” it writes in a press release.

There’s a lot of tracking going on here so it’s clearly not the simplest personalized health message. But Tayfun said the team was frustrated with the limitations of other health/wellness trackers and at-home test kits — wanting something more comprehensive as well as the gratification of instant results. Hence setting out to build Vivoo.

“This was definitely personal for me,” she tells TechCrunch. “I’m a bioengineer, and I wanted to know everything I could about my own health. Prior to creating Vivoo, I had tried every kind of tracker and test — wearables, tests like 23 and Me, blood tests like Everlywell — I wanted to know it all. But it was costly, and the results were rarely real time. Sometimes it could take 1-2 months to get specific metrics.

“As a bioengineer, I knew there had to be a better way. So we created a wellness tracker based on at-home urine tests that gives instant results and engaging, personalized recommendations to help people improve and manage their health on their own.”

Per Tayfun the “key data points” the app currently reads are: hydration, pH, Ketones, UTIs, kidney and liver scores.

“With the premium experience, we extended the tests and our customers will be able to track their Magnesium like minerals, Vitamin C, Free Radicals, and salt consumption,” she adds.

What scientific research is Vivoo drawing on to make recommendations based on its (remote) analysis of users’ urine samples?

“Our approach is to suggest evidence-based recommendations created by dieticians and reviewed by doctors,” she responds on that, further specifying: “The research mainly uses higher-quality scientific research such as meta-analysis, systematic reviews, and nutritional guidelines. Additionally, the impact factor and scientific journal ranking is also taken into account when selecting a reference.”

Some of the information on Vivoo’s website talks about the importance of ‘balancing’ the pH of urine. Asked about this she says urinary pH has a “close association with the dietary acid load”.

“Diet composition has long been known to influence acid-base balance by providing acid or base precursors. In general, foods rich in protein, such as meat, cheese, eggs, and others, increase the production of acid in the body, whereas fruit and vegetables increase alkalis,” she says.

“The capacity of acid or base production of any food is called potential renal acid load (PRAL). While human urine can range from 4.5 to 8, The optimal urine should be around 6-7. Having too acidic or too alkaline urine has some health risks.”

So this means that the app might flag that a user’s urine is ‘too acidity’ — and say that’s linked with eating more High-PRAL (aka “High acidic”) foods — which Tayfun suggests causes “metabolic acidosis” that she says has been associated with the development of a number of chronic diseases, such as diabetes, insulin resistance, hypertension, chronic kidney disease, renal lithiasis and non-alcoholic fatty liver, “among others”.

“In this case, we show the possible health risks and suggest low-PRAL (Alkaline promoting) foods to balance the ‘acidic’ urine pH and lower the health risks,” she goes on, suggesting generally that checking their urine pH regularly will help Vivoo users to be “more proactive, learn more about their body and get help with choosing mindful food options to improve their wellbeing”.

On the website Vivoo recommends users do a weekly test of their urine — although it suggests that those tracking their hydration or ketones might feel nudged to test more often. (Although the current subscription packs don’t provide enough test kits for users to maintain daily testing without a break.)

Vivoo’s speedy remote analysis of users’ urine test strips hinges on machine learning models that Tayfun says were trained on “more than 1M data points to give precise results”.

Although she qualifies that by saying the database is growing “day by day” to add more info on “different light conditions, camera models, phone models and softwares of the mobile devices to be accurate in multiple platforms”.

And, well, as the app itself is not a medical device the analysis it performs is just a data operation, not a medical diagnosis — so performance/accuracy is obviously not akin to a medical-grade device.

Asked how it’s assessed the accuracy of the scanning component of the analysis, Tayfun says that for the Vivoo Lite product the image processing system has been tested in external laboratories and in its own labs.

“Measurements are carried out simultaneously in the tests and comparative analyzes are made. Phones with different operating systems and camera features are used in accuracy tests,” she says, adding: “Comparative analyzes in urine analysis devices are measured by looking at two percentiles, which are 100% accurate and +-1 level error of measurement values.”

She also specifies that a new Premium subscription tier of the product will also undergo a third party laboratory and analysis — with results slated to be published in a peer-reviewed journal (but that hasn’t happened yet).

“Our urine tests are registered with the FDA but the app is not as it’s not a diagnostic device but a data tracking tool,” she adds when asked whether Vivoo has plans to apply for the app to be regulated as a medical device in the future.

“We have plans to extend the capabilities of the application in the future, and we may consider adding metrics that can help chronic disease sufferers to track and share their data with their healthcare professionals. We will be following the FDA’s guidelines and recommendations as always if we choose that approach.”

In the nearer term, Vivoo will be beefing up the product proposition and looking to scale revenue with a premium tier.

“As we added more metrics into our urine tests, we realized wearable integration and even Genetic data integration can be a
huge benefit for our customers to better understand what is going inside their bodies,” Tayfun suggests, adding: “We will be making major updates from November to February on a monthly basis so stay tuned!”

“The main benefit of allowing our customers to integrate their wearable data is that now they will be able to crossmatch their sleep, activity, and heart data with Vivoo’s urine metrics. A simple example is seeing you had a bad night of sleep is ‘ok data’ but visualizing your sleep data with your hydration and magnesium data, will give you more actionable items about how you can improve your sleep via nutrition and simple daily activities. Same for period cramps, heart health, even mood swings, and mindfulness.”

While commercial momentum is clearly building to encourage the ‘worried well’ to quantify and track various bits of their biology, there are likely to be limits on how many of these wellness trackers/test kits/subscription services even a highly ‘health conscious’ individual is going to be prepared to shell out for.

Vivoo’s push to cover a wide range of trackable metrics — including by bolting on additional at home tests kits (presumably expanding out from urine analysis) — looks like a play to cover as many bases as possible so it can sell consumers on a single subscription service for all their wellness tracking needs.

Asked about the competitive landscape, Tayfun says its current perspective is that technologies that are using “different body data and science-base” are complementary to Vivoo’s approach — and she extends an invite to fellow founders for API integrations “if the customer consents”; (adding: “We believe together we can change bad habits to goods more easily! More data will allow our technologies to provide better insights and recommendations.”)

However she also agrees that consumers will have a finite budget for wellness tracking.

“We’d like to position Vivoo as a one-stop shop by covering a big area of wellness, nutrition, mindfulness, activity, and sleep on the line. But we don’t have expertise in all of these verticals so working with well-established partners such as Apple, Calm, Oura, Whoop and collaborations as such would benefit both the customers and companies to provide better insights to customers,” she says, adding: “Also, I believe more data will improve products as well. You might see you’re lactose intolerant in 23 and Me and dairy can be your superfood in Viome, anonymized data can guide us to be more precise, and improve the company’s science and technology.”

Research remains a priority for the startup — which says it will continue to spend a fifth of its budget on R&D.

Tayfun confirms that this includes doing research on what she describes as “anonymized data” from users — trailing “amazing findings” it plans to publish (“in late 2022”), such as the “most hydrated States and state water fountain regulations” and “ketones and personal income (rich cities starve themselves more!)”.

Commenting on the Series A in a supporting statement, Draper describes “personalized data driven health care” as a “major theme” for Draper Associates.

“Miray and her team at Vivoo are collecting personalized data frictionlessly through a simple at-home pee test with actionable advice that allows customers to be proactive about their health,” he said, adding: “Wellness has become such a high priority over the past year, with more people taking proactive control of their health. We’re excited to work with Vivoo as the company expands its footprint globally.”

After already targeting verticals like hotels and apartment complexes, Amazon announced today it’s now rolling out new solutions for healthcare providers and senior living centers. The solutions, which are a part of Alexa Smart Properties, are designed specifically to meet the needs of deploying Alexa devices at scale and will allow the facility’s administrators to create customized experiences for their residents or patients.

In senior living centers, the residents would be able to use Alexa devices to call their family members and other loved ones, as well as keep up with the goings-on at their community and other community news. The devices could also be used to make announcements, allow the residents to communicate with each other through direct audio messages, make voice and video calls, and they can streamline other center activities — like check-ins, maintenance requests, and various administrative tasks. Amazon believes this could help make facilities more efficient and productive.

Amazon says senior living communities include Atria and Eskaton will integrate with its new solution.

The market for using Alexa in senior living communities was already being explored by third-party providers, like K4Connect, which last year closed on $21 million in Series B funding to bring newer technologies, including Alexa’s voice assistance, to older adults and those living with disabilities. Companies like K4Connect and others, including Lifeline Senior Living, Aiva, and Vocera, can now tap into Alexa Smart Properties’ tools and APIs to make it easier for them to roll out their own, customized solutions and software.

Image Credits: Amazon

Meanwhile, Amazon had already piloted putting Alexa in patient rooms in a test with Cedars-Sinai, which allowed patients to use voice commands for performing basic tasks, like changing TV channels, as well as communicating with caregivers. The idea was that, by offloading some of the everyday tasks to Alexa, it could free up nurses to focus more on medical care.

With Amazon’s new solution for hospitals, patients will be able to use Alexa to communicate with care staff, control the devices in their room, and stay entertained with news and music. Healthcare providers can also communicate with their patients using Alexa features like calling and Drop-In, without having to enter the patient rooms. This could also help hospitals be more productive and conserve their medical supplies and protective equipment like gloves, masks, and gowns, notes Amazon. (PPE shortages had been an ongoing issue in some locations as Covid spiked during the pandemic.)

Cedars-Sinai is among those officially rolling out the Alexa Smart Properties solution, following its pilot program, and is joined by BayCare and Houston Methodist, Amazon says.

“Voice is intuitive for patients, regardless of age or tech-savviness,” said Peachy Hain, executive director of Medical and Surgical Services at Cedars-Sinai, in a statement. “Since it’s so easy to operate, patients can use Alexa to connect with their care team and stay entertained as soon as they settle in, while care providers can streamline tasks to make more time to care for those patients. It’s a total gamechanger for enhancing our hospital experience,” Hain added.

Though Amazon has struggled with privacy issues related to its use of voice recordings and transcriptions, the healthcare and senior living center solutions will not save the voice recordings and don’t require users to share personal info with Alexa to use the device, the company explains. Users can also mute the Echo’s microphone at any time with the button on top. Amazon also claims it safeguards protected health information received through HIPAA-eligible Alexa skill interactions.

Amazon has been working to bring Alexa to healthcare facilities for some time. A report in 2018 by CNBC had said the company was building out a healthcare team with Alexa in order to make the voice assistant useful in the industry. This included working through the complex HIPAA regulations that would be required to do so. The following year, Amazon announced its first HIPAA-compliant medical skills and began piloting its devices in hospitals. Elsewhere across Amazon, the company has invested in healthcare solutions in other ways, including through solutions like Amazon Comprehend Medical, a machine learning tool that gathers information from things like doctors’ notes and patient health records, and acquisitions like online pharmacy PillPack.

Both of the new Alexa Smart Properties solutions will roll out in the U.S. starting next month, Amazon says.

Meet Wefight, a French startup that has developed more than a dozen apps to help people suffering from chronic illness. Using a basic chatbot interface, people can ask questions and get answers about their illness.

The startup recently raised a $11.6 million (€10 million) funding round from Digital Health Ventures, Impact Partners, as well as existing investors Investir&+ and BADGE’s business angels.

Wefight has developed a different app for each chronic illness. They’re all based on the same virtual assistant called Vik. There are currently more than a dozen apps about depression, asthma, multiple cancers, etc.

Essentially, Vik acts as an interface between the patient and Wefight’s content. The company has developed everything in-house, from natural-language processing technology to the framework that Wefight leverages to create new apps.

Every time a patient asks a question, the service tries to understand the meaning of the question and finds relevant information in the knowledge database.

It can then relay and serve content to the patient. Content has been written by professional pharmacists and tries to be as informative and neutral as possible. This way, you don’t necessarily have to wait for your next doctor’s appointment to go through your list of questions.

“Vik isn’t going to replace someone in the care pathway. It’s there to fill a gap,” co-founder and CEO Benoit Brouard told me.

And it seems like there’s a gap indeed. More than 400,000 people have tried the service so far. Vik has delivered 5 million answers. There are 70 people working for Wefight right now. Wefight tries to find new users by talking with patient organizations.

When it comes to the business model, Wefight works with pharmaceutical companies to finance new apps. Turning a treatment into a commercial success involves making sure that patients can identify the chronic illness they’re suffering from. And Vik acts as a top-of-the-funnel content provider.

“We reduce clinical inertia. When a lab decides to finance Vik Asthma, the lab doesn’t have any influence on the content that we create,” Brouard said. “Laboratories want patients who suffer from asthma to go and see a pulmonologist,” he added.

This way, the pool of patients who could potentially end up buying a specific drug is bigger. It’s a convoluted sales strategy for pharmaceutical companies. But something like Vik could improve the quality of life of patients.

With today’s funding round, the company plans to expand to other countries with a new office in Berlin. Every time Wefight launches an app in a new market, the company hires local health professionals and contact local patient organizations. It’s a long process, but that’s how Wefight can get it right for patients all around the world.